Search Results
Your search for Christopher J. Sweeney, MBBS matches 6 pages
Showing 1 - 6Long-Term Survival Outcomes With Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Analysis of long-term survival outcomes in the phase III CHAARTED trial showed a survival advantage with the addition of docetaxel to androgen-deprivation therapy (ADT) in patients with hormone-sensitive metastatic prostate cancer, although no advantage was observed among patients with low-volume...
PSA at 7 Months and Prognosis in Metastatic Hormone-Sensitive Prostate Cancer Treated With ADT With or Without Chemotherapy
In a study reported in the Journal of Clinical Oncology, Harshman et al found that a prostate-specific antigen (PSA) level ≤ 0.2 ng/mL at 7 months after the start of androgen-deprivation therapy (ADT) was significantly associated with longer overall survival in metastatic...
Metastasis-Free Survival as Surrogate for Overall Survival in Localized Prostate Cancer
In a meta-analysis reported in the Journal of Clinical Oncology, Xie et al found that metastasis-free survival was a strong surrogate for overall survival in patients with localized prostate cancer, potentially providing a metric that could accelerate assessment of new adjuvant therapy approaches. ...
Christopher J. Sweeney, MBBS, on Prostate Cancer: CHAARTED Trial Follow-up
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)
Christopher J. Sweeney, MBBS, on Localized Prostate Cancer: Metastasis-Free Survival as a Surrogate for Overall Survival
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermediate and high-risk prostate cancer. (Abstract 717O)
ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...
